Yanai K - Search Results

1

Liprin-α4 as a New Therapeutic Target for SCLC as an Upstream Mediator of HIF1α.

Onishi H, Yamasaki A, Nakamura K, Ichimiya S, Yanai K, Umebayashi M, Nagai S, Morisaki T. Onishi H, et al. Among authors: yanai k. Anticancer Res. 2019 Mar;39(3):1179-1184. doi: 10.21873/anticanres.13227. Anticancer Res. 2019. PMID: 30842147

2

Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells.

Xu R, Sato N, Yanai K, Akiyoshi T, Nagai S, Wada J, Koga K, Mibu R, Nakamura M, Katano M. Xu R, et al. Among authors: yanai k. Anticancer Res. 2009 Jan;29(1):261-70. Anticancer Res. 2009. PMID: 19331159 Free article.

3

Hedgehog Inhibition Upregulates TRK Expression to Antagonize Tumor Suppression in Small Cell Lung Cancer Cells.

Onishi H, Nakamura K, Nagai S, Yanai K, Yamasaki A, Kawamoto M, Imaizumi A, Morisaki T. Onishi H, et al. Among authors: yanai k. Anticancer Res. 2017 Sep;37(9):4987-4992. doi: 10.21873/anticanres.11910. Anticancer Res. 2017. PMID: 28870922

4

Liprin-α4 as a Possible New Therapeutic Target for Pancreatic Cancer.

Yamasaki A, Nakayama K, Imaizumi A, Kawamoto M, Fujimura A, Oyama Y, Nagai S, Yanai K, Onishi H. Yamasaki A, et al. Among authors: yanai k. Anticancer Res. 2017 Dec;37(12):6649-6654. doi: 10.21873/anticanres.12122. Anticancer Res. 2017. PMID: 29187440

5

RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer.

Onishi H, Ichimiya S, Yanai K, Umebayashi M, Nakamura K, Yamasaki A, Imaizumi A, Nagai S, Murahashi M, Ogata H, Morisaki T. Onishi H, et al. Among authors: yanai k. Anticancer Res. 2018 Aug;38(8):4543-4547. doi: 10.21873/anticanres.12758. Anticancer Res. 2018. PMID: 30061220

6

Hypoxia and pancreatic ductal adenocarcinoma.

Yamasaki A, Yanai K, Onishi H. Yamasaki A, et al. Among authors: yanai k. Cancer Lett. 2020 Aug 1;484:9-15. doi: 10.1016/j.canlet.2020.04.018. Epub 2020 May 5. Cancer Lett. 2020. PMID: 32380129 Review.

7

TrkB/BDNF Signaling Could Be a New Therapeutic Target for Pancreatic Cancer.

Oyama Y, Nagao S, Na L, Yanai K, Umebayashi M, Nakamura K, Nagai S, Fujimura A, Yamasaki A, Nakayama K, Morisaki T, Onishi H. Oyama Y, et al. Among authors: yanai k. Anticancer Res. 2021 Aug;41(8):4047-4052. doi: 10.21873/anticanres.15205. Anticancer Res. 2021. PMID: 34281873

8

PTPN3 Could Βe a Therapeutic Target of Pancreatic Cancer.

Onishi H, Iwamoto N, Sakanashi K, Koga S, Oyama Y, Yanai K, Nakamura K, Nagai S, Fujimura A, Nakayama K, Ozono K, Yamasaki A. Onishi H, et al. Among authors: yanai k. Anticancer Res. 2022 Jun;42(6):2869-2874. doi: 10.21873/anticanres.15768. Anticancer Res. 2022. PMID: 35641270

9

Anti-patched-1 antibodies suppress hedgehog signaling pathway and pancreatic cancer proliferation.

Nakamura M, Kubo M, Yanai K, Mikami Y, Ikebe M, Nagai S, Yamaguchi K, Tanaka M, Katano M. Nakamura M, et al. Among authors: yanai k. Anticancer Res. 2007 Nov-Dec;27(6A):3743-7. Anticancer Res. 2007. PMID: 17970037 Free article.

10

Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway.

Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, Wada J, Yanai K, Koga K, Sato N, Kubo M, Tanaka M, Onishi H, Katano M. Ikebe M, et al. Among authors: yanai k. J Surg Oncol. 2009 Dec 15;100(8):725-31. doi: 10.1002/jso.21392. J Surg Oncol. 2009. PMID: 19722233

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

528 results

Search Page